MedTrace Logo

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

NCT04101838 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-14

No results posted yet for this study

Summary

This study will examine how various FDA-approved seasonal influenza vaccine types, used in a manner consistent with their approved use, impact the characteristics of influenza specific antibodies in humans, and how these responses differ based on age and prior immunization history.

Conditions

Interventions

DRUG

Fluzone

inactivated seasonal influenza vaccine

DRUG

Flucelvax

inactivated seasonal influenza vaccine

DRUG

Fluzone High-Dose

inactivated seasonal influenza vaccine

DRUG

Fluad

inactivated seasonal influenza vaccine

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • James J Kobie, PhD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2026-05-11
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04101838 on ClinicalTrials.gov